Pembrolizumab

Strength: 50 mg; 100 mg

Dosage Form: IV concentrate

Description:

Pembrolizumab is an immune checkpoint inhibitor (anti-PD-1 antibody) used to treat various cancers by activating the immune system to target tumor cells.

Key Features:

• Immune-based cancer therapy
• Used in melanoma, lung, head and neck, and other cancers
• Administered by IV infusion

Precautions:

May cause immune-related adverse events affecting lungs, liver, and endocrine glands. Monitor closely.